Clinical Trial Results: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel in combination with alpelisib for anthracycline-refractory triple-negative breast cancer with PIK3CA or PTEN alterations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2026-07-07